Carlos BalmacedaManuel A. EspinozaTomas AbbottAnne Peters2023-01-272023-01-272022Balmaceda, C., Espinoza, M. A., Abbott, T., & Peters, A. (2022). Cost-effectiveness analysis: Fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system. Expert Review of Pharmacoeconomics & Outcomes Research, 22(5), 743-751. https://doi.org/10.1080/14737167.2022.2044308https://investigadores.udd.cl/handle/123456789/562610.1080/14737167.2022.20443082-s2.0-85126094359WOS:000765619100001cost-effectiveness analysischronic obstructive pulmonary diseasesingle inhaler triple therapyquality-adjusted life yearschileandrostadienesbenzyl alcoholsbronchodilator agentschilechlorobenzenescost-benefit analysisdouble-blind methoddrug combinationsfluticasoneforced expiratory volumehumanspublic healthpulmonary disease, chronic obstructivequinuclidinestreatment outcomefluticasone furoate plus umeclidinium plus vilanterolfluticasone furoate plus vilanterolfluticasone propionate plus salmeteroltiotropium bromideumeclidinium plus vilanterolandrostane derivativebenzyl alcohol derivativebronchodilating agentchlorobenzenefluticasonefluticasone furoatequinuclidine derivativeumeclidiniumvilanterolarticlechronic obstructive lung diseasecohort analysiscost effectiveness analysisgross national producthumanpublic healthsensitivity analysistreatment outcomechilechronic obstructive lung diseasecost benefit analysisdouble blind proceduredrug combinationforced expiratory volumeCost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health systemResource Types::text::journal::journal article